New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
07:27 EDTGSK, PFE, LLY, SNY, NVSDrug companies targeting myostatin, WSJ reports
Drug companies, including Novartis (NVS), Eli Lilly (LLY), Sanofi (SNY), Pfizer (PFE) and Glaxosmithkline (GSK), are looking make a drug that targets myostatin, a naturally occurring protein that curbs muscle growth, the Wall Street Journal reports. All the companies' drugs are in clinical or earlier-stage testing, and the first drug could be approved in 2016. Reference Link
News For NVS;LLY;GSK;SNY;PFE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
January 23, 2015
06:39 EDTGSKNIH, GlaxoSmithKline, Merck launch joint Ebola vaccine test in Liberia, WSJ says
Subscribe for More Information
January 22, 2015
11:23 EDTPFEPfizer says CHMP adopted positive opinion on Prevenar 13 expansion
Subscribe for More Information
05:22 EDTSNYGenzyme Cerdelga granted marketing authorization by EC
Subscribe for More Information
January 21, 2015
12:35 EDTNVSNovartis confirms FDA approval for Cosentyx
Subscribe for More Information
12:33 EDTNVSFDA approves Novartis psoriasis drug Cosentyx
Subscribe for More Information
12:30 EDTGSK, PFEGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
10:26 EDTNVSHigh option volume stocks
Subscribe for More Information
10:16 EDTSNY, LLYLeerink biopharma analysts hold an analyst/industry conference call
Analyst Fernandez, along with Dr. Paul Gurbel and Dr. Richard Becker, discuss AstraZeneca's PEGASUS trial and the current use of Brilinta and dual antiplatelet therapy for prevention of CV disease and implications of the recently completed DAPT trial on an Analyst/Industry conference call to be held on January 21 at 1:30 pm.
January 16, 2015
08:31 EDTNVS, GSKGlaxoSmithKline CEO says more IPOs like ViiV could happen, Retuers says
Subscribe for More Information
January 15, 2015
14:31 EDTGSKMylan launches generic Epivir-HBV tablets
Mylan (MYL) announced the U.S. launch of its Lamivudine Tablets, 100 mg, which is the generic version of GlaxoSmithKline's (GSK) Epivir-HBV. Mylan received final approval from the U.S. FDA for its Abbreviated New Drug Application for this product, which is indicated for the treatment of chronic hepatitis B virus infection associated with evidence of hepatitis B viral replication and active liver inflammation. Lamivudine Tablets, 100 mg, had U.S. sales of approximately $18.1M for the 12 months ending September 30, 2014, according to IMS Health. Currently, Mylan has 284 ANDAs pending FDA approval representing $109.1B in annual brand sales, according to IMS Health. Forty-four of these pending ANDAs are potential first-to-file opportunities, representing $29.3B in annual brand sales, for the 12 months ending June 30, 2014, according to IMS Health.
11:20 EDTPFE, LLYGoldman cuts J&J to sell citing competitive pressures
Subscribe for More Information
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:36 EDTGSKOncoMed enrolls first biomarker-selected patient in Notch1 antibody Phase trial
Subscribe for More Information
07:59 EDTPFEAmerican Society of Clinical Oncology to hold a symposium
Subscribe for More Information
07:07 EDTLLYEli Lilly upgraded at Goldman
As previously reported, Goldman upgraded Eli Lilly to Neutral from Sell. The firm upgraded shares based on new product launches and pipeline assets, and cost reductions. Price target is $70.
06:44 EDTLLYEli Lilly upgraded to Neutral from Sell at Goldman
Subscribe for More Information
January 14, 2015
11:45 EDTNVSImmunoGen discloses triggering of $5M milestone payment from Novartis
Subscribe for More Information
January 13, 2015
12:40 EDTLLYAmgen off highs after Express Scripts CEO talks PCSK9 costs
Subscribe for More Information
08:08 EDTLLYEli Lilly, Merck enter collaborationa greement to evaluate Keytruda, compounds
Merck (MRK) and Eli Lilly and Company (LLY) announced an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Merck will conduct a Phase 2 study examining the combination of pembrolizumab with pemetrexed in first-line non-squamous, non-small cell lung cancer. This study is currently enrolling. Lilly will conduct a multiple-arm Phase 1/2 study examining the combination of ramucirumab with pembrolizumab in multiple tumors. This study is anticipated to begin in 2015. Lilly will conduct a Phase 1/2 study examining the combination of necitumumab with pembrolizumab in NSCLC. This study is anticipated to begin in 2015. The agreement is between Lilly and Merck, through a subsidiary. Additional details of the collaboration were not disclosed.
08:05 EDTLLYBristol-Myers Eli Lilly enter clinical collaboration pact for Opdivo combo
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use